Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma

Misato Kikuchi, Hideki Nakasone, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Kana Sakamoto, Koji Kawamura, Yuko Ishihara, Miki Sato, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun Ichi Kimura, Rie Yamazaki, Shinichi Kako, Junya Kanda, Junji Nishida, Naohiro Sekiguchi, Satoshi NotoMichiko Kida, Akira Hangaishi, Kensuke Usuki, Yoshinobu Kanda

研究成果: Article査読

8 被引用数 (Scopus)

抄録

Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.

本文言語English
ページ(範囲)99-105
ページ数7
ジャーナルJournal of Chemotherapy
27
2
DOI
出版ステータスPublished - 2015
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 薬理学
  • 薬理学(医学)
  • 感染症

フィンガープリント

「Reduced-dose (Two-thirds) R-CHOP chemotherapy for elderly patients with non- hodgkin lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル